Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer

Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). Considering the exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiangping, Han, Jiaqi, Zhang, Yalan, Muhetaer, Muhelisa, Chen, Nianyong, Yan, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500475/
https://www.ncbi.nlm.nih.gov/pubmed/36160459
http://dx.doi.org/10.3389/fphar.2022.924126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500475/
https://www.ncbi.nlm.nih.gov/pubmed/36160459
http://dx.doi.org/10.3389/fphar.2022.924126

Ejemplares similares